AstraZeneca PLC (AZN) Analysts See $0.28 EPS on May, 18

May 17, 2018 - By Jack Shaw

AstraZeneca PLC (NYSE:AZN) Corporate Logo

AstraZeneca PLC (NYSE:AZN)’s quarterly earnings will be reported on May, 18 before the open., Faxor reports. The EPS diference is $0.71 or 71.72 % down from last years number. Previous year: $0.99; Analysts forcast: $0.28. The profit will be $697.23M for AZN if $0.28 EPS becomes true. After $1.30 EPS report last quarter, Wall Street now predicts -78.46 % negative EPS growth of AstraZeneca PLC. The stock increased 0.72% or $0.26 during the last trading session, reaching $36.5.AstraZeneca PLC has volume of 3.44M shares. Since May 17, 2017 AZN has risen 9.03% and is uptrending. AZN underperformed by 2.52% the S&P500.

AstraZeneca PLC (NYSE:AZN) Ratings Coverage

Total analysts of 5 have positions in AstraZeneca (NYSE:AZN) as follows: 4 rated it a “Buy”, 0 with “Sell” and 1 with “Hold”. The positive are 80%. The firm has $42.0 highest while $36.0 is the lowest price target. The average target $40 is 9.59% above the last ($36.5) price. Since December 29, 2017 according to StockzIntelligence Inc AstraZeneca has 6 analyst reports. The stock rating was maintained by Leerink Swann with “Market Perform” on Tuesday, February 6. The stock rating was upgraded by Jefferies to “Buy” on Monday, March 19. In Friday, December 29 report JP Morgan upgraded the stock to “Overweight” rating. The stock rating was maintained by Leerink Swann with “Hold” on Thursday, January 18. On Friday, December 29 the firm earned “Buy” rating by J.P. Morgan. In Monday, February 5 report Bernstein maintained the stock with “Buy” rating.

AstraZeneca PLC discovers, develops, makes, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, infection, gastrointestinal, and neuroscience diseases worldwide.The company has $90.89 billion market cap. The Company’s marketed products comprise Arimidex, Casodex/Cosudex, Faslodex, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Imdur, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Symlin, Xigduo, and Xigduo XR for metabolic diseases.The P/E ratio is 30.8. The companyÂ’s marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, and Symbicort Turbuhaler for respiratory diseases; Fluenz Tetra/FluMist Quadrivalent and Synagis for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, Vimovo1, and Zomig for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases.

A couple more AstraZeneca PLC (NYSE:AZN) news were released by: Streetinsider.com which released on May 15, 2018 “AstraZeneca (AZN) PT Raised to $41 at BMO Capital”, also Streetinsider.com on May 16, 2018 released “AstraZeneca (AZN) Said to Weigh Sale of US Rights to Crestor, Could Fetch Over $1 Billion – Bloomberg”, the next Nasdaq.com is “3 Dividend Stocks to Fund Your Nest Egg” on May 16, 2018. Benzinga.com has article titled “AstraZeneca Shares Are Looking Very Weak Right Now”.

AstraZeneca PLC (NYSE:AZN) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: